Celltrion Inc
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
Phase 1
Completed
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: CT-P59
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 18
- Registration Number
- NCT04593641
- Locations
- 🇰🇷
Incheon Medical Center, Incheon, Korea, Republic of
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 32
- Registration Number
- NCT04525079
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Biological: EU-approved ProliaBiological: CT-P41
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 30
- Registration Number
- NCT04512872
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Biological: CT-P43Biological: US-licensed StelaraBiological: EU-approved Stelara
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 271
- Registration Number
- NCT04428814
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Grafton, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Limited, Christchurch, Canterbury, New Zealand
To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
Phase 3
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: EU-approved XolairBiological: CT-P39
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 634
- Registration Number
- NCT04426890
- Locations
- 🇵🇱
Klinika Ambroziak ESTEDERM, Warszawa, Poland
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
Phase 1
Terminated
- Conditions
- Cardiomyopathy, Hypertrophic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 23
- Registration Number
- NCT04418297
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇵🇱Institute of Cardiology in Warsaw, Warsaw, Mazowieckie, Poland
To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: CT-P17
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 180
- Registration Number
- NCT04295356
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
Phase 3
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: CT-P13 SC (Infliximab)Other: Placebo SC
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 548
- Registration Number
- NCT04205643
- Locations
- 🇵🇱
Centrum Zdrowia MDM, Warszawa, Poland
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: CT-P17 SC AI (adalimumab)
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 62
- Registration Number
- NCT04171414
- Locations
- 🇵🇱
Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Poland
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: EU-approved XolairBiological: CT-P39Biological: US-licensed Xolair
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 176
- Registration Number
- NCT04018313
- Locations
- 🇦🇺
Phase 1 unit, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath